COMP <GO>
NATL vs DBD // REVENUE GROWTH (YOY)
NCR Atleos Corporation (NYSE) VS. Diebold Nixdorf Incorporated (NYSE) • 15-METRIC TALLY: NATL 7
— DBD 4
▲ REVENUE GROWTH (YOY) LEADER: DBD
LAST: $45.71 (+0.93%) • MKT CAP: $3.38B
revenue-growth
1.10%
LAST: $59.14 (+1.84%) • MKT CAP: $1.99B
revenue-growth
1.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NATL VS. DBD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NATL | DBD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 25.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.40% | 11.50% | +2.90 | NATL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.7x | 10.6x | -0.90 | NATL | /valuation <GO> |
| Free Cash Flow Yield | 7.08% | 15.14% | -8.06 | DBD | /fcf-yield <GO> |
| Operating Margin | 11.00% | 6.40% | +4.60 | NATL | /operating-margins <GO> |
| Net Profit Margin | 3.70% | 2.50% | +1.20 | NATL | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 1.10% | 1.50% | -0.40 | DBD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.49 | 1.79 | -0.30 | DBD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | DBD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.1 | 27.7 | +19.46 | NATL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.4x | 19.5x | -0.10 | NATL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.38B | $1.99B | $1.39B | NATL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NATL REV | DBD REV | NATL GROSS % | DBD GROSS % | NATL FCF | DBD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.35B | $3.81B | — | 25.3% | $239.0M | $300.7M |
| FY 2024 | $4.30B | $3.75B | — | 24.5% | $257.0M | $149.2M |
| FY 2023 | $4.19B | — | — | — | $355.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NATL // BETA —
DBD // BETA —